The bipartisan bill is backed by more than 250 organizations, but ACMG remains opposed, arguing that ordering tests is part of the practice of medicine.
Medicare Administrative Contractor Palmetto released its final local coverage decision last year, and WPSIC has now aligned its coverage.
Scheduled to go into effect next year, CMS' price transparency regulations could drive down reimbursements but also streamline billing for hospital labs.
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
A pair of lawyers familiar with the case said that while ACLA might not win the legal battle, its lawsuit could aid efforts to get a legal fix to the law.
Ravitej Reddy pleaded guilty in federal court to allegations he illegally billed Medicare for cancer genomic testing and pharmacogenetic testing.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
News items for the in vitro diagnostics industry for the week of Dec. 30, 2019
The LCD for the RNA gene expression test will take effect on Feb. 10, 2020, the Medicare contractor said.
Despite the availability of more precision therapies and complex biomarker tests, systemic gaps and lack of physician education continued to hinder access.